Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome.
Kalyoncu
Nuri I
NI
Department of Pharmacology, Karadeniz Technical University, School of Medicine, Trabzon, Turkey.
Yaris
Fusun
F
Kadioglu
Mine
M
Kesim
Murat
M
Ulku
Cunay
C
Yaris
Ersin
E
Unsal
Mesut
M
Dikici
Mustafa
M
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007783:Lactones / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000188:drug therapy*; D000077403:Orlistat; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome; D017257:Ramipril / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents; D007783:Lactones; D013453:Sulfonylurea Compounds; C057619:glimepiride; D000077403:Orlistat; D017257:Ramipril